Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090612 | 0.84 | ADRB2 (0.52) | ADRB2ADRB1ADRB3MAPK1 | |
| SCHEMBL13892852 | 0.82 | MAPK1 (0.46) | ADRB2ADRB1ADRB3MAPTMAPK1 | |
| SCHEMBL3060193 | 0.80 | ADRB2 (0.59) | ADRB2ADRB1ADRB3PDE4BMAPK1 | |
| SCHEMBL2056234 | 0.80 | MAPK1 (0.46) | ADRB2ADRB1ADRB3MAPTMAPK1 | |
| SCHEMBL3060189 | 0.80 | ADRB2 (0.59) | ADRB2ADRB1ADRB3PDE4BMAPK1 | |
| SCHEMBL13617661 | 0.78 | ADRB2 (0.62) | ADRB2ADRB1ADRB3 | |
| SCHEMBL13100668 | 0.76 | ADRB1 (0.37) | ADRB2ADRB1ADRB3PDE4B | |
| SCHEMBL18415171 | 0.75 | MAPK1 (0.41) | ADRB2ADRB1ADRB3MAPTMAPK1 | |
| SCHEMBL11671740 | 0.74 | ADRB2 (0.61) | ADRB2ADRB1ADRB3MAPK1 | |
| SCHEMBL2056232 | 0.74 | ADRB2 (0.65) | ADRB2ADRB1ADRB3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885ADRB1 1/4885ADRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.